Search

Displaying results 2551 - 2560 of 5392 in total
  1. Drug

    Declopramide

    go.drugbank.com/drugs/DB06421
    Experimental

  2. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. … [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC.

  3. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products.

  4. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...

  5. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon- and ribavirin-based regimens, which were limited by infusion site reactions, reduced blood

  6. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance ...

  7. Drug

    Meclocycline

    go.drugbank.com/drugs/DB13092
    Investigational

    Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .

  8. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...

  9. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.

  10. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.